Physician profile
Walter John Murrell
NPI 1598734634
$3,606.78
in general payments reported to CMS, 2019-2025
20 companies · $311 in 2025
The $311 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $493 · 2020: $356 · 2021: $586 · 2022: $628 · 2023: $983 · 2024: $251 · 2025: $311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,495 · Honoraria: $27.78 · Gift: $21.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,495.16 |
| Honoraria | $27.78 |
| Gift | $21.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,844.03 | 2019-2024 | Clareon, Centurion |
| Horizon Therapeutics Plc | $604.81 | 2021-2023 | Tepezza |
| Rxsight INC | $130.20 | 2023-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Amgen INC. | $126.66 | 2024-2025 | Tepezza |
| Mallinckrodt Enterprises LLC | $123.41 | 2019 | |
| Biotissue Holdings INC. | $102.71 | 2025 | |
| Bausch & Lomb Americas INC. | $100.82 | 2022-2025 | Scoutpro Osmolarity System, Vyzulta, Xiidra |
| Ocular Therapeutix, INC. | $95.27 | 2022 | |
| Abbvie INC. | $85.63 | 2023 | |
| Tarsus Pharmaceuticals, INC. | $65.17 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $62.59 | 2022-2023 | |
| Glaukos Corporation | $61.37 | 2022 | |
| Tearlab Corp | $42.64 | 2024 | Scoutpro Osmolarity System |
| Allergan, INC. | $30.74 | 2020-2021 | |
| Merz Pharmaceuticals, LLC | $30.59 | 2023 | Xeomin |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $24.43 | 2022 | |
| Sight Sciences, INC. | $23.44 | 2023 | Omni Surgical System |
| Glaxosmithkline, LLC. | $19.98 | 2019 | |
| Genentech USA, INC. | $16.92 | 2021 | |
| Harrow Eye, LLC | $15.37 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Murrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.